Want to see QTTB full AI Analyst Report?
QTTB Stock Chart & Stats
$16.32
-$0.23(-1.50%)
At close: 4:00 PM EDT
$16.32
-$0.23(-1.50%)
Day’s Range― - ―
52-Week Range$1.69 - $23.57
Previous CloseN/A
Volume178.84K
Average Volume (3M)509.46K
Market Cap
$332.52M
Enterprise Value$158.19
Total Cash (Recent Filing)$106.27M
Total Debt (Recent Filing)$5.30M
Price to Earnings (P/E)3.9
Beta0.22
Next Earnings
Nov 05, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.79
Shares Outstanding29,769,466
10 Day Avg. Volume682,597
30 Day Avg. Volume509,464
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.97
Price to Sales (P/S)0.76
P/FCF Ratio-1.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$41.00Price Target Upside151.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.45
Revenue Forecast (FY)$333.33K
Bulls Say, Bears Say
Bulls Say
Clinical ValidationThe 36-week Phase 2a results provide meaningful clinical validation for bempikibart in severe alopecia areata, combining measurable hair-growth improvement with a favorable safety profile. This supports advancement toward registration-directed development and potential expansion across related autoimmune indications.
Late-stage LeadershipAdding executives with experience taking therapies through late-stage development, FDA approval and commercialization strengthens execution capability at a critical transition point. Their expertise may improve trial design, regulatory preparation and launch planning as bempikibart advances.
Improved Balance SheetLow current debt relative to equity and the completed loan payoff provide greater financial flexibility than the prior capital structure. A simpler balance sheet can reduce financing pressure and preserve resources for clinical development, despite the company remaining dependent on funding.
Bears Say
No Commercial Revenue BaseBecause Q32 Bio remains focused on clinical development rather than selling approved therapies, it lacks a recurring commercial revenue base to fund operations. Financial progress therefore depends heavily on successful development, regulatory milestones and access to external financing.
Persistent Cash BurnNegative operating and free cash flow show that the business is not yet self-funding, even after improvement from the larger 2024 outflow. Continued clinical investment will require financing or other capital sources, increasing sensitivity to funding availability over coming quarters.
Volatile Earnings QualityThe sharp shift from earlier losses and minimal or negative revenue to reported TTM profitability makes current earnings difficult to view as a stable operating trend. Such volatility reduces confidence in forecasting durable earnings and complicates assessment of underlying business performance.
Q32 Bio News
QTTB FAQ
What was Q32 Bio’s price range in the past 12 months?
Q32 Bio lowest stock price was $1.69 and its highest was $23.57 in the past 12 months.
What is Q32 Bio’s market cap?
Q32 Bio’s market cap is $332.52M.
When is Q32 Bio’s upcoming earnings report date?
Q32 Bio’s upcoming earnings report date is Nov 05, 2026 which is in 49 days.
How were Q32 Bio’s earnings last quarter?
Q32 Bio released its earnings results on Aug 05, 2026. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.46 by $0.02.
Is Q32 Bio overvalued?
According to Wall Street analysts Q32 Bio’s price is currently Undervalued.
Does Q32 Bio pay dividends?
Q32 Bio does not currently pay dividends.
What is Q32 Bio’s EPS estimate?
Q32 Bio’s EPS estimate is -0.33.
How many shares outstanding does Q32 Bio have?
Q32 Bio has 29,769,466 shares outstanding.
What happened to Q32 Bio’s price movement after its last earnings report?
Q32 Bio reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.46. Following the earnings report the stock price went up 2.074%.
Which hedge fund is a major shareholder of Q32 Bio?
Currently, no hedge funds are holding shares in QTTB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Q32 Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.00 (151.23% Upside)
$41.00 (151.23% Upside)
Blogger Sentiment
Bullish
QTTB Sentiment 86%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $275.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.2%
Last 30 Days ▲ 23.1%
Last 30 Days ▲ 23.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
517.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
75.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Q32 Bio
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
QTTB Stock 12 Month Forecast
Average Price Target
$41.00
▲(151.23% Upside)
Technical Analysis
Tempest Therapeutics
―
PDS Biotechnology
―
Grace Therapeutics
―
CalciMedica
―
Senti Biosciences
―
Ownership Overview
6.57% Insiders
1.55% Mutual Funds
63.35% Other Institutional Investors
23.01% Public Companies and
Individual Investors